Servier is the second largest pharmaceutical group in France and the 31st largest in the world treating over 100 million patients worldwide. But where does Malaysia fit in and what prospects do we offer the company?



Roshan Kanesan speaks to Servier Malaysia's General Manager, Kshitij Panse, about their Malaysian presence, their growth in oncology, rationale for not having Asian production facilities, and doing business in Malaysia.



Image credit: Shutterstock & Servier Malaysia

Servier is the second largest pharmaceutical group in France and the 31st largest in the world treating over 100 million patients worldwide. But where does Malaysia fit in and what prospects do we offer the company?

Roshan Kanesan speaks to Servier Malaysia's General Manager, Kshitij Panse, about their Malaysian presence, their growth in oncology, rationale for not having Asian production facilities, and doing business in Malaysia.

Image credit: Shutterstock &amp; Servier Malaysia

Sharper and stronger than a double espresso. The Morning Run stretches your mind and braces you for the business day. It's your fast track into work where you can hit the ground running. From 6am to 10am weekdays, the Morning Run brings you the biggest stories and must-listen-to interviews. Stay enlightened, make educated business and investment decisions.

The Breakfast Grille

Featuring the cream-of-the-crop as well as the controversial, the Breakfast Grille is the flagship show of BFM. Expect no-holds-barred interviews to get to the truth and into the minds of business leaders, policymakers and changemakers.

Malaysia's Importance To Pharma Giant Servier

UCSI University, which in 2024 found itself at its highest position in the QS World University Rankings since its inception, slipped slightly in the 2025 list. Datuk Dr Siti Hamisah Tapsir, the university's Vice-Chancellor, discusses whether UCSI University can sustain its position as competition intensifies and weighing in on Malaysia’s higher education system.

UCSI University, which in 2024 found itself at its highest position in the QS World University Rankings since its inception, slipped slightly in the 2025 list. Datuk Dr Siti Hamisah Tapsir, the university's Vice-Chancellor, discusses whether UCSI University can sustain its position as competition intensifies and weighing in on Malaysia’s higher education system.

UCSI University: Competition in the Higher Education Space

Telco tower veteran Suresh Sidhu launched EdgePoint Infrastructure in 2020, scaling the regional venture to over 16,000 sites across Malaysia, Indonesia, and the Philippines, with backing from DigitalBridge, and then later the Abu Dhabi Investment Authority.

However the infrastructure model now faces a more complex reality: carrier consolidation and a higher for longer interest rate environment that creates a more challenging environment, in particular for a PE-backed player. Can ASEAN’s underlying tide of data demand outrun these mounting structural pressures?

Suresh Sidhu joins the show to discuss navigating private equity expectations in a high-rate climate, the shifting economics of a consolidated customer base, and the new growth engines driving the TowerCo model.

Telco tower veteran Suresh Sidhu launched EdgePoint Infrastructure in 2020, scaling the regional venture to over 16,000 sites across Malaysia, Indonesia, and the Philippines, with backing from DigitalBridge, and then later the Abu Dhabi Investment Authority.However the infrastructure model now faces a more complex reality: carrier consolidation and a higher for longer interest rate environment that creates a more challenging environment, in particular for a PE-backed player. Can ASEAN’s underlying tide of data demand outrun these mounting structural pressures?Suresh Sidhu joins the show to discuss navigating private equity expectations in a high-rate climate, the shifting economics of a consolidated customer base, and the new growth engines driving the TowerCo model.

Can ASEAN’s Digital Needs Push EdgePoint Past Key Pressures?

Pharmaniaga officially exited PN17 status in March, having taken three years to complete its regularisation plan. The firm is now vying to become the most valuable pharmaceutical company in Malaysia by 2030 leveraging on its ongoing government concession in logistics and biopharma manufacturing capabilities. We catch-up with Managing Director Dato’ Zulkifli Jafar to find out how he intends to achieve this goal.

Pharmaniaga officially exited PN17 status in March, having taken three years to complete its regularisation plan. The firm is now vying to become the most valuable pharmaceutical company in Malaysia by 2030 leveraging on its ongoing government concession in logistics and biopharma manufacturing capabilities. We catch-up with Managing Director Dato’ Zulkifli Jafar to find out how he intends to achieve this goal.

Malaysia's Importance To Pharma Giant Servier

In 1 playlist(s)

The Breakfast Grille

Social links

Follow podcast

Recent clips